39 research outputs found
Supplementary Data from Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab
Supplementary Data from Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozituma
Supplemental Figure 1 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
FGFR3 knockdown reduces MMP-1 and MMP-10 mRNA expression in RT112 cells.</p
Supplemental Figure 4 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
R3Mab reduces MMP protein secretion in the conditioned medium by UMUC-14 cells.</p
Supplemental Figure 5 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
R3Mab attenuates xenograft growth of UMUC-14 tumors.</p
Supplemental Figure 8 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Lack of effect of R3Mab on serum pro-MMP-10 levels in mice with SW780 tumors.</p
Supplemental Table 2 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
List of patient information in the phase I study.</p
Supplemental Figure 2 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
FGFR3 siRNA and R3Mab diminish MMP-1 and MMP-10 mRNA leves in UMUC-14 cells.</p
Supplemental Table 1 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Contains a list of genes regulated by FGFR3 shRNA in RT112 cells.</p
Supplemental Figures 6 and 7 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
R3Mab reduces serum levels of human MMP-1 and pro-MMP-10 in mice bearing bladder tumor xenografts.</p
Supplemental Figure 3 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
FGFR3 knockdown in RT112 cells reduces total MMP-10 protein level in conditioned medium.</p